This publication reinforces ADMA's manufacturing quality narrative but provides no new financial data or guidance. Monitor upcoming quarterly results for revenue growth from ASCENIV and BIVIGAM, and any FDA labeling changes or competitive positioning updates.
Price Chart
Executive Summary
ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine detailing data from its optimized IVIG manufacturing process. The study of three commercial-scale lots showed effective removal of procoagulant impurities (Factor XIa, IgA, IgM, cholesterol, prekallikrein activator) while maintaining immunoglobulin quality and increasing IgG yield. No thromboembolic events were reported in postmarketing surveillance from July 2025 through July 2026. This is a quality/safety validation event, not a financial catalyst, and the study's small sample size (3 lots) and limited surveillance period limit its impact.
Key Facts
- Peer-reviewed publication in Frontiers in Cardiovascular Medicine on optimized IVIG manufacturing process
- Three commercial-scale lots tested; all procoagulant impurities at or below quantification limits
- Two of three lots had Factor XIa below limit of quantification
- Average NAPTT >250 seconds (threshold >200 seconds associated with reduced TEE incidence)
- No thromboembolic events reported in postmarketing surveillance July 2025–July 2026
- Optimized process increased immunoglobulin yield while maintaining quality
- Study limitations: only 3 lots evaluated, limited surveillance period, spontaneous reporting subject to underreporting
Financial Impact
No financial figures provided; publication is a quality/safety validation, not a revenue or earnings event
Risk Factors
- Small sample size (3 lots) limits generalizability of findings
- Postmarketing surveillance period is relatively short (13 months) and subject to underreporting
- Thrombosis remains a labeled risk for all IVIG products, including ADMA's
- No financial impact or guidance provided in this release
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381479 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $10.73 | awaiting T+60 | — | $10.98 (+2.33%) |
Aug 8, 2026 11w ago | Institutional Cluster | $9.75 | awaiting T+60 | — | $10.98 (+12.62%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.21 $9.54 | ▲ +16.20% | ▲ +12.94% | $10.98 (+33.74%) |
May 4, 2026 25w ago | 8-K | $10.31 $8.71 | ▼ −15.52% | ▼ −17.38% | $10.98 (+6.50%) |
Apr 15, 2026 27w ago | DEFA14A | $10.74 $8.97 | ▼ −16.48% | ▼ −23.53% | $10.98 (+2.23%) |
Mar 27, 2026 30w ago | Press Release | $9.25 $8.72 | ▼ −5.78% | ▼ −21.85% | $10.98 (+18.70%) |
Feb 25, 2026 34w ago | 8-K | $15.18 $8.46 | ▼ −44.27% | ▼ −52.02% | $10.98 (−27.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers